Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Characteristics of subjects with very low serum low-density lipoprotein cholesterol and the risk for intracerebral hemorrhage.

Lee JG, Koh SJ, Yoo SY, Yu JR, Lee SA, Koh G, Lee D.

Korean J Intern Med. 2012 Sep;27(3):317-26. Epub 2012 Sep 1.

2.

Clinicoradiological profile and serum lipid levels of intracerebral hemorrhage in prior statin users.

Miura K, Yoshii Y, Nakamura Y, Ikeda K.

Intern Med. 2011;50(13):1385-91. Epub 2011 Jul 1.

3.

Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage.

Rodriguez-Luna D, Rubiera M, Ribo M, Coscojuela P, Pagola J, Piñeiro S, Ibarra B, Meler P, Maisterra O, Romero F, Alvarez-Sabin J, Molina CA.

Stroke. 2011 Sep;42(9):2447-52. doi: 10.1161/STROKEAHA.110.609461. Epub 2011 Jul 28.

4.

Association of prestroke statin use and lipid levels with outcome of intracerebral hemorrhage.

Mustanoja S, Strbian D, Putaala J, Meretoja A, Curtze S, Haapaniemi E, Sairanen T, Hietikko R, Sirén J, Kaste M, Tatlisumak T.

Stroke. 2013 Aug;44(8):2330-2. doi: 10.1161/STROKEAHA.113.001829. Epub 2013 Jun 11.

5.

Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.

Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, Inada T, Mitsuoka H, Taniguchi R, Nakano A, Kita T, Sakata R, Kimura T; CREDO-Kyoto PCI/CABG registry cohort-2 investigators.

Circ J. 2012;76(6):1369-79. Epub 2012 Mar 15.

6.

Mixed dyslipidemias in primary care patients in France.

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E.

Vasc Health Risk Manag. 2012;8:247-54. doi: 10.2147/VHRM.S27668. Epub 2012 Apr 19.

7.

Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage.

Haussen DC, Henninger N, Kumar S, Selim M.

Stroke. 2012 Oct;43(10):2677-81. Epub 2012 Jul 24.

8.

HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.

Tani S, Nagao K, Hirayama A.

Am J Cardiovasc Drugs. 2011 Dec 1;11(6):411-7. doi: 10.2165/11594620-000000000-00000.

PMID:
22149320
9.

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials.

McKinney JS, Kostis WJ.

Stroke. 2012 Aug;43(8):2149-56. doi: 10.1161/STROKEAHA.112.655894. Epub 2012 May 15. Review.

10.

[Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study].

González-Juanatey JR, Cordero A, Vitale GC, González-Timón B, Mazón P, Bertomeu V.

Rev Esp Cardiol. 2011 Oct;64(10):862-8. doi: 10.1016/j.recesp.2011.05.022. Epub 2011 Aug 10. Spanish.

11.

Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease.

Takamiya Y, Miura S, Kawamura A, Tanigawa H, Zhang B, Iwata A, Nishikawa H, Matsuo K, Shirai K, Saku K.

Coron Artery Dis. 2009 Jun;20(4):288-94. doi: 10.1097/MCA.0b013e32832c4538.

PMID:
19440067
12.

Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study.

Tani S, Saito Y, Anazawa T, Kawamata H, Furuya S, Takahashi H, Iida K, Matsumoto M, Washio T, Kumabe N, Nagao K, Hirayama A.

Int Heart J. 2011;52(6):343-7.

13.
16.

The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.

Pennell P, Leclercq B, Delahunty MI, Walters BA.

Clin Nephrol. 2006 Nov;66(5):336-47.

PMID:
17140163
17.

Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.

González CA, Rubio-Guerra AF, Pavía A, Redding FJ, Cervantes JL, Zacarías JL, Yza R, Carranza J, Fernández P, Morales E, Robles FJ, Leyva JL, Rodríguez L.

Clin Drug Investig. 2007;27(5):333-7.

PMID:
17451281
18.

Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage.

Ramírez-Moreno JM, Casado-Naranjo I, Portilla JC, Calle ML, Tena D, Falcón A, Serrano A.

Stroke. 2009 May;40(5):1917-20. doi: 10.1161/STROKEAHA.108.536698. Epub 2009 Mar 19.

19.

Association of low cholesterol with primary intracerebral haemorrhage: a case control study.

Orken DN, Kenangil G, Celik M, Mail Z, Kayaalp H, Erginoz E, Forta H.

Acta Neurol Scand. 2009 Mar;119(3):151-4. doi: 10.1111/j.1600-0404.2008.01083.x. Epub 2008 Aug 5.

PMID:
18684213
20.

The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D.

Am J Cardiovasc Drugs. 2006;6(6):383-91.

PMID:
17192128
Items per page

Supplemental Content

Write to the Help Desk